Glykind 60 XR Tablet contains Gliclazide 60 mg, an oral hypoglycemic agent belonging to the sulfonylurea class, primarily indicated for the management of type 2 diabetes mellitus. It functions by stimulating insulin secretion from the pancreatic beta cells, thereby improving glycemic control in patients with non-insulin-dependent diabetes. The extended-release (XR) formulation ensures a gradual and sustained release of the active ingredient, promoting stable blood glucose levels over a 24-hour period and reducing the frequency of dosing. Glykind 60 XR is typically prescribed as part of a comprehensive diabetes management plan that includes diet, exercise, and lifestyle modifications. It is particularly beneficial for patients inadequately controlled by diet alone or in combination with other antidiabetic agents. The medication should be used cautiously in patients with hepatic or renal impairment, and monitoring of blood glucose levels is essential to minimize the risk of hypoglycemia. Common adverse effects may include hypoglycemia, gastrointestinal disturbances, and allergic reactions. Glykind 60 XR Tablet should be administered under medical supervision, with dosage adjustments based on therapeutic response and patient tolerance to optimize efficacy and safety.